FRAZER, Pa., Feb. 7 /PRNewswire/ -- Cephalon, Inc. today announced the promotion of Mike Barr to Vice President and General Manager of Cephalon’s Salt Lake City manufacturing, packaging and distribution facility, effective immediately.
(Photo: http://www.newscom.com/cgi-bin/prnh/20070207/PHW018 )
Barr will continue his current responsibilities of managing the facility, overseeing production of Cephalon products and representing the company in the Salt Lake City community.
“Cephalon has developed into one of the largest life sciences companies in Utah, and Mike has been integral to this growth and has enhanced the level of cooperation with the State,” said Peter E. Grebow, Ph.D., Executive Vice President of Worldwide Technical Operations.
Since Barr assumed responsibility for the site, it has grown from 90 employees in 1998 to more than 212 employees working in a 300,000-square-foot, world-class Good Manufacturing Practices (GMP) pharmaceutical complex.
For the last two years, Barr oversaw the construction of Cephalon’s facility expansion in Salt Lake City, which opened last August. This facility is producing FENTORA(TM) (fentanyl buccal tablet) [C-II], the company’s next- generation therapy for the management of breakthrough pain in opioid-tolerant patients with cancer.
Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company’s headquarters in Frazer, Pa., and offices, laboratories or manufacturing facilities in West Chester, Pa.; Salt Lake City, and suburban Minneapolis. Cephalon’s European headquarters are located in Maisons-Alfort, France.
The company currently markets six proprietary products in the United States: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA, ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II], GABITRIL(R) (tiagabine hydrochloride), TRISENOX(R) (arsenic trioxide) injection, and VIVITROL(R) (naltrexone for extended-release injectable suspension). Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; intellectual property protection for its products; interpretation of clinical results; manufacturing development and capabilities; market prospects for its products; sales and earnings guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Cephalon’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070207/PHW018AP Archive: http://photoarchive.ap.orgAP PhotoExpress Network: PRN11PRN Photo Desk, photodesk@prnewswire.comCephalon, Inc.
CONTACT: Media, Sheryl Williams of Cephalon, Inc., +1-610-738-6493, orswilliam@cephalon.com
Web site: http://www.cephalon.com/
Company News On-Call: http://www.prnewswire.com/comp/134563.html /
